SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz among traders who are attracted to its active developer engagement and the community's push to build organic momentum, despite the project's early stage and lack of an official chart. Investors are actively discussing the potential for a significant breakout, emphasizing the need for sustained volume and broader social media promotion to move the token toward mainstream visibility.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy (MULN CRYPTO) is currently trending as members debate its viability, with many in the community labeling it a pump-and-dump scheme or comparing it to the Mullen Automotive stock decline. While some users attempt to rally interest through community-led narratives and crypto-market speculation, others are actively warning investors to exit to avoid potential financial losses.

iShares Inc. - iShares MSCI Mexico ETF

iShares MSCI Mexico ETF

Investors are actively debating the long-term viability of Mexico as a manufacturing hub, with some noting its strategic importance in nearshoring supply chains while others warn of socio-economic decay and political risks. The community is focused on the impact of trade tariffs and US-Mexico relations on the performance of $EWW.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors monitor its development as a rare earth metals processor amid increasing urgency for U.S.-aligned supply chains. The community is actively debating the stock's long-term potential in the defense sector, with heavy discussions focused on the company's advisory board appointments, defense-related contracts, and the risks versus rewards associated with future production timelines.

ETF Series Solutions - ESS U.S.Global Jets ETF

US Global Jets ETF

Airline stocks are facing renewed volatility as the sector grapples with potential operational disruptions, fuel cost pressures, and broader economic uncertainty. The community is actively debating the sustainability of travel demand and debating whether the recent price action offers a contrarian value opportunity or a warning of deeper industry headwinds.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals is trending following an Endpoints News report alleging that FDA Commissioner Marty Makary attempted to force a rejection of the company's hereditary angioedema (HAE) drug application, an effort that was reportedly blocked by internal FDA scientists. Investors are actively discussing the stock's resilience, as the company maintains its path toward potential approval for the first oral on-demand treatment for HAE while bulls view the resulting price volatility as a favorable opportunity to increase positions.

Investment Managers Series Trust II - Tradr 1.5X Short NVDA Daily ETF

Tradr 1.5X Short NVDA Daily ETF

The $NVDS ETF is seeing intense activity as traders debate whether Nvidias rally is sustainable or if a major pullback is imminent. The community is heavily focused on using this inverse instrument as a tactical hedge or aggressive short, with active discussions weighing technical support levels and the risks of betting against such a volatile market leader.

ETF Opportunities Trust - T-Rex 2X Inverse Tesla Daily Target ETF

T-Rex 2X Inverse Tesla Daily Target ETF

TSLZ is trending as investors aggressively hedge against Tesla's volatility following contentious leadership remarks and mixed earnings, with significant community debate focused on the company's valuation versus its growth prospects. Traders are actively utilizing the inverse ETF to capitalize on concerns regarding slowing EV demand and high-profile management scrutiny.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Guy is gaining traction as investors rally behind its status as an iconic, original meme, with the community actively promoting its restored meme-generation tools and historical roots on the Solana network. Supporters are focused on long-term conviction and 'bagwork,' positioning the token as a primary contender in the current meme coin cycle by emphasizing its deep cultural heritage and utility for content creation.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The XRP community remains deeply divided, with some investors accumulating tokens in anticipation of regulatory clarity and institutional adoption, while others express frustration over long-term price stagnation and perceived lack of progress. Debates are currently fueled by speculation surrounding the Clarity Act and the expansion of Ripple's payment infrastructure, leading to a polarized environment between optimistic long-term holders and disillusioned skeptics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The healthcare sector could be gearing up for its next big move. For the past few weeks, the index has been consolidating, which is often considered a good sign. Stocks or sectors that consolidate before a breakout usually see strong momentum once the breakout happens.&nbsp;SEBI-registered&nbsp;<a href="https://stocktwits.com/Ca_mayankchandel">analyst Mayank Singh Chandel</a> noted that the healthcare sector is trading very close to its all-time high, which is also acting as a resistance zone. He has flagged four stocks to watch from this space for potential upside in the future.&nbsp;Fortis HealthcareChandel believes that&nbsp;<a href="https://stocktwits.com/symbol/FORTIS.NSE">Fortis</a> is currently the strongest stock in the healthcare space. It’s trading at an all-time high and has shown solid momentum recently. However, it’s better to avoid fresh entries right now and wait for a healthy pullback.&nbsp;Fortis Health has gained 51% year-to-date (YTD).Apollo HospitalsFor&nbsp;<a href="https://stocktwits.com/symbol/APOLLOHOSP.NSE">Apollo Hospitals</a>, Chandel said that the stock is in a long-term uptrend and forming an ascending triangle pattern. A breakout above ₹8,000 could open the door for a strong upward move.&nbsp;Apollo Hospitals has gained 5% YTD.<stembedurl>https://stocktwits.com/Ca_mayankchandel/message/632003631</stembedurl>Aurobindo Pharma<a href="https://stocktwits.com/symbol/AUROPHARMA.NSE">Aurobindo</a> was trading near its support zone. If the healthcare sector shows strength, this stock is also likely to bounce back, according to him.&nbsp;The stock has shed 15% so far this year.&nbsp;Torrent Pharmaceuticals<a href="https://stocktwits.com/symbol/TORNTPHARM.NSE">Torrent Pharma</a> is currently inside a descending triangle pattern. Once it breaks out on the upside, the stock has a high probability of showing good momentum, Chandel added.&nbsp;Torrent Pharma has gained 5% YTD.He advised traders to closely monitor the healthcare sector, adding that a a breakout from here could trigger a new rally in several healthcare names.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

A staffer stands at the monitor in the pharmacy on October 1, 2025. (Photo by Carsten Koall/picture alliance via Getty Images)

Breakout Brewing In Healthcare Stocks: SEBI Analyst Sees Potential In These Four Stocks

The analyst highlights Fortis Healthcare, Apollo Hospitals, Aurobindo Pharma, and Torrent Pharma as key stocks to watch.

Equity

Indian drug imports into the U.S. are set to&nbsp;become more expensive after U.S. President Donald Trump announced a 100% tariff, effective&nbsp;from October.That move is expected to put pressure on Indian pharmaceutical companies that earn a large share of their revenues from the American market.Analyst View&nbsp;SEBI-registered investment advisor&nbsp;<a href="https://stocktwits.com/thetradebond">Nidhi Saxena</a> stated that the tariffs could spark near-term volatility in several frontline Indian pharmaceutical stocks. She highlighted support and resistance levels to watch:<stembedurl>https://stocktwits.com/thetradebond/message/630084317</stembedurl><ul><li>Sun Pharma: Support at ₹1,560, resistance at ₹1,645</li><li>Dr. Reddy’s: Support at ₹1,240, resistance at ₹1,305</li><li>Cipla: Support at ₹1,475, resistance at ₹1,535</li><li>Lupin: Support at ₹1,900, resistance at ₹1,975</li><li>Aurobindo Pharma: Support at ₹1,065, resistance at ₹1,110</li><li>Zydus Lifesciences: Support at ₹970, resistance at ₹1,010</li><li>Torrent Pharma: Support at ₹3,480, resistance at ₹3,600</li><li>Biocon: Support at ₹335, resistance at ₹355</li><li>Glenmark: Support at ₹1,955, resistance at ₹2,025</li></ul>“These tariffs will make branded pharma imports into the U.S. much costlier,” Saxena said, adding that companies with higher U.S. revenue exposure, such as Sun Pharma, Dr. Reddy’s, Cipla, Lupin and Aurobindo Pharma could see sharp swings.Asian Pharma SlideThe fallout extended beyond India. In Asia, several major pharmaceutical and biotech companies closed lower after Trump’s announcement.&nbsp;Daiichi Sankyo tumbled 3.34%, Chugai Pharma lost 2.18%, and Sumitomo Pharma slipped 3.03%. Samsung Biologics was down 1.66%, SK Biopharma dropped 2.66%, WuXi Biologics slid 2.95%, Alibaba Health fell 1.84%, and Sino Biopharma eased 1.25%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Will Trump’s 100% Tariffs Derail Indian Pharma Stocks? SEBI Analyst Flags Key Levels For Traders

The new U.S. duty has already triggered a slide in major Asian pharma names, raising concerns about how Indian peers will react in the coming weeks.

Healthcare stocks in India fell on Friday as investors weighed the impact of U.S. President Donald Trump’s move to impose a 100% tariff on branded and patented drugs starting Oct. 1.&nbsp;The measure, announced in late-night Truth Social posts, exempts only those manufacturers with U.S. plants that are already under construction or have broken ground.The Nifty Healthcare index fell 1.2% on Thursday, with 18 of its 20 components trading lower.&nbsp;IPCA Laboratories remained unchanged, while Torrent Pharma rose 0.01%.Analyst ViewSEBI-registered analyst&nbsp;<a href="https://stocktwits.com/ra_vishaltrehan">Vishal Trehan</a> said Gland Pharma is the most exposed, given its lack of a U.S. manufacturing footprint and reliance on branded or patented formulations.&nbsp;<stembedurl>https://stocktwits.com/ra_vishaltrehan/message/630078378</stembedurl>He noted that Syngene International, Piramal Pharma, and Zydus Lifesciences stand to benefit from their contract manufacturing models and biologics portfolios, which are less tariff-sensitive.Trehan also pointed out that companies with a large branded generics or biosimilars presence, such as Dr. Reddy’s Laboratories and Biocon, will need to accelerate U.S. production to avoid margin erosion.Trump’s Pharma TariffsThe announcement builds on Trump’s escalating trade measures aimed at repatriating drug manufacturing. Last month, he outlined a phased plan, beginning with a “small tariff” on imported drugs, before lifting duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had earlier been excluded from his reciprocal tariff program, but the new rules extend to prescription medicines, biologics, specialty drugs, and over-the-counter products, with generic drugs remaining exempt.What Is The Retail Mood?On Stocktwits, retail sentiment for Piramal Pharma, Zydus Lifesciences, and Dr. Reddy’s Laboratories was ‘bearish’ amid ‘normal’ message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/GLAND.NSE">Gland Pharma</a> has risen 6.5%, while&nbsp;<a href="https://stocktwits.com/symbol/SYNGENE.NSE">Syngene International</a> is down 29.1%,&nbsp;<a href="https://stocktwits.com/symbol/PPLPHARMA.NSE">Piramal Pharma</a> has slipped 25.9%,&nbsp;<a href="https://stocktwits.com/symbol/ZYDUSLIFE.NSE">Zydus Lifesciences</a> is up 1.8%,&nbsp;<a href="https://stocktwits.com/symbol/DRREDDY.NSE">Dr. Reddy’s Laboratories</a> is down 7.2%, and&nbsp;<a href="https://stocktwits.com/symbol/BIOCON.NSE">Biocon</a> has fallen 6.3%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

India’s Healthcare Index Sinks After Trump’s Pharma Tariff Blow — SEBI Analyst Sees Risks For Gland, Biocon, Dr. Reddy’s

The analyst noted that Syngene, Piramal Pharma, and Zydus Lifesciences may be better positioned, as their contract manufacturing models and biologics portfolios are less susceptible to the tariff impact.

India’s healthcare sector has received a boost from the latest round of Goods and Services Tax (GST) reform.The government has lowered GST across several products and services in the healthcare basket, making treatments and coverage more affordable while creating volume opportunities for companies.What Got CheaperHealth and life insurance, previously taxed at 18%, will now attract no GST at all. Thermometers have been reduced from 18% to 5%. Medical-grade oxygen, diagnostic kits, reagents, glucometers, and test strips have all seen rates cut from 12% to 5%.&nbsp;Corrective spectacles also shift from 12% to 5%. Finkhoz said these cuts translate into lower costs for consumers and stronger demand across healthcare services and products.Technical ViewSEBI-registered platform&nbsp;<a href="https://stocktwits.com/Finkhoz">Finkhoz</a> said the Nifty Healthcare index is consolidating just below the key resistance zone of 14,800–15,000, noting that the index is forming an inverted head-and-shoulders pattern, with the neckline around the same zone.&nbsp;<stembedurl>https://stocktwits.com/Finkhoz/message/628102110</stembedurl>A breakout above 14,800–15,000, if supported by volume, could trigger a rally toward 15,800–16,200, while strong support is placed at 14,000.Stocks To WatchPrivate hospitals, such as Apollo Hospitals and Fortis Healthcare, could see an increase in demand as wider insurance coverage makes it easier for patients to choose private care.&nbsp;Diagnostic players like Metropolis Healthcare and Dr Lal Pathlabs are also likely to benefit, with cheaper kits expected to drive more people toward regular testing and higher volumes.&nbsp;Medical device makers such as Poly Medicure are positioned to benefit from lower GST on devices and reagents. Optical businesses, including Titan Company’s Titan Eye+, may also see a lift from cheaper spectacles.&nbsp;Insurance players like HDFC Life, ICICI Prudential, and SBI Life could be major winners, with tax-free health insurance described by Finkhoz as a “game-changer.”Analyst ViewFinkhoz said the GST cuts are not only about affordability but also about broadening access to healthcare.&nbsp;More insurance adoption, cheaper diagnostics, and lower device costs are expected to create steady growth opportunities across healthcare and insurance. “For investors, healthcare just got its booster shot,” the analyst concluded.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Healthcare Stocks Get A GST Boost: Index Nears Breakout; Bull Run Likely In Apollo, Fortis, Dr Lal, Poly Medicure 

The analyst said the GST cut expands access to care while opening steady opportunities for companies in the sector.

Current Price	13,934.35
Prev Close	14,055.75
Open	13,855.75
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

NIFTYHEALTHCARE.NSE
NIFTY HEALTHCARE

Feed

News

Sentiment

Fundamentals

Info

Latest NIFTYHEALTHCARE.NSE News

NIFTYHEALTHCARE.NSENIFTY HEALTHCARE